Simplex Trading
ZNTL icon

Simplex Trading’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Simplex Trading’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$165K Sell
59,536
-19,368
-25% -$78.1K ﹤0.01% 4849
2026
Q2 		$383K Sell
78,904
-19,650
-20% -$78.4K ﹤0.01% 3947
2026
Q1 		$231K Buy
+98,554
New +$255K ﹤0.01% 4135
2025
Q3 		– Sell
-9,699
Closed -$14.5K – 10251
2025
Q2 		$11K Buy
9,699
+8,154
+528% +$10.8K ﹤0.01% 7278
2025
Q1 		$2K Buy
+1,545
New +$3.33K ﹤0.01% 8108
2024
Q4 		– Sell
-267
Closed -$875 – 9805
2024
Q3 		$0 Sell
267
-300
-53% -$1.09K ﹤0.01% 9754
2024
Q2 		$2K Buy
+567
New +$6.33K ﹤0.01% 8371
2024
Q1 		– Sell
-31,078
Closed -$427K – 10089
2023
Q4 		$470K Buy
31,078
+28,865
+1,304% +$421K ﹤0.01% 3768
2023
Q3 		$44K Buy
+2,213
New +$56.2K ﹤0.01% 5933

Other funds holding ZNTL

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Decheng Capital
Decheng Capital Menlo Park, California $685M AUM 129.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Simplex Trading's ZNTL Position: Q3 2026 in Review

Simplex Trading reduced its Zentalis Pharmaceuticals (ZNTL) stake by 25% in Q3 2026, selling an estimated $78.1K and leaving 59,536 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #4849.

Simplex Trading first reported a position in ZNTL in Q3 2023 and has held it in 9 quarters since. The position peaked at $470K in Q4 2023. 81 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

  • Simplex Trading held 59,536 shares of Zentalis Pharmaceuticals worth $165K as of Q3 2026.
  • Simplex Trading sold 19,368 Zentalis Pharmaceuticals shares in Q3 2026, an estimated $78.1K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #4849 holding.
  • Simplex Trading first reported a position in Zentalis Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • Simplex Trading's Zentalis Pharmaceuticals position peaked at $470K in Q4 2023.
  • 81 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.